All Articles

Real-world evidence indicates robust biosimilar uptake of the first FDA-approved bevacizumab biosimilar, bevacizumab-awwb, across its approved indications, including metastatic colorectal cancer and non–small-cell lung cancer.

The findings from a small, retrospective study suggest that same-day pegfilgrastim-cbqv was a safe and effective alternative to standard administration 24 hours postchemotherapy for the primary and secondary prophylaxis of febrile neutropenia with myelosuppressive chemotherapy in patients with breast cancer.

A retrospective study conducted in Poland confirmed that treatment with trastuzumab-anns was associated with an acceptable cardiac safety profile, even when switching from trastuzumab reference or when combined with pertuzumab.

Preliminary findings of this retrospective study indicate that treatment with bevacizumab reference product may be associated with a higher risk for hypertension and proteinuria, whereas treatment with bevacizumab biosimilars correlated with shorter onset of these adverse events.

The results of the cost-efficiency analysis within the Centers for Medicare & Medicaid Services Oncology Care Model indicate that switching from reference pegfilgrastim to pegfilgrastim-jmdb provided cost-savings that could potentially be reallocated to food and transportation support.

A real-world retrospective study (Canadian population) showed that patients with HER2-positive neoadjuvant early breast cancer treated with trastuzumab-dkst versus trastuzumab achieved similar pCR rates.

Patients who take immune checkpoint inhibitors experience a small number of severe side effects, although the majority of them recover with treatment.

Sotorasib and adagrasib show promising clinical activity against KRAS^G12C mutations in patients with NSCLC, giving new hope for patients with the previously regarded “undruggable” disease.

A subgroup analysis of the CodeBreaK 100 trial results found that sotorasib achieved a positive response in pretreated patients with KRAS^G12C mutation–positive NSCLC subtypes.

A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.